Target intelligence / Profile preview

Fibroblast growth factor 8 (FGF8)

Target
FGF8
Molecular classification
Growth factor, Signaling molecule, Cytokine, Heparin-binding protein
01

Overview

Fibroblast growth factor 8 (FGF8) is a secreted signaling protein belonging to the fibroblast growth factor family, with vital roles in embryonic development, organogenesis, cell proliferation, differentiation, and tissue repair[1][3][7]. FGF8 is particularly crucial for neural and limb development, midbrain-hindbrain patterning, and the emergence of gonadotropin-releasing hormone neurons, and it signals through fibroblast growth factor receptors (primarily FGFR1) to mediate its effects[1][3][7]. Abnormal FGF8 activity or mutations are linked to congenital disorders such as Kallmann syndrome and various cancers, making it a potential, albeit challenging, therapeutic target in oncology, skeletal disease, and endocrinology[1][3][5].

Other names
Fibroblast growth factor 8FGF8AIGFFGF-8HBGF-8androgen-induced growth factorheparin-binding growth factor 8HH6KAL6
02

Mechanism of action

FGFR inhibitors: block FGF8-induced receptor activation and downstream signaling. Experimental antibodies or ligand traps: block FGF8 binding to its receptor[5].

03

Biological functions

Cell proliferationCell survivalEmbryonic developmentNeural developmentLimb developmentTissue repairMorphogenesisPatterning of body axes and germ layersRegulation of chondrocyte (cartilage cell) proliferation and differentiation
04

Disease associations

CancerCongenital hypogonadotropic hypogonadism (including Kallmann syndrome)OsteoarthritisSkeletal malformationsOther developmental disorders
05

Safety considerations

FGF8 is critical for embryonic development and tissue homeostasis; systemic inhibition could disrupt development or tissue repairOn-target toxicities may include endocrine or neurodevelopmental effects
06

Interacting drugs

No selective, approved drugs target FGF8 directly. Interference is experimental; some small molecules or biologics targeting the FGF/FGFR axis (e.g., FGFR inhibitors) may impact FGF8 signaling
07

Biomarkers

FGF8 expression (experimental) as a potential biomarker for certain cancersMutations in FGF8 as biomarkers for Kallmann syndrome and other developmental syndromes

Beyond the preview

Go deeper on Fibroblast growth factor 8 (FGF8).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fibroblast growth factor 8 (FGF8).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call